{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:08:34Z","timestamp":1793909314044,"version":"4.8.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T cell therapy targeting CD19 elicits remarkable clinical efficacy in B cell malignancies, but many patients relapse owing to failed expansion and\/or progressive loss of CAR-T cells. We recently reported a strategy to potently restimulate CAR-T cells in vivo, enhancing their functionality by administration of a vaccine-like stimulus comprised of surrogate peptide ligands for a CAR linked to a lymph node-targeting amphiphilic PEG-lipid (amph-vax). Here we demonstrate a general strategy to discover and optimize peptide mimotopes enabling amph-vax generation for any CAR. We use yeast surface display to identify peptide binders to FMC63 (the scFv used in clinical CD19 CARs), which are then subsequently affinity matured by directed evolution. CAR-T vaccines using these optimized mimotopes triggered marked expansion and memory development of CD19 CAR-T cells in both syngeneic and humanized mouse models of B-acute lymphoblastic leukaemia\/lymphoma, and enhanced control of disease progression compared with CD19 CAR-T-only-treated mice. This approach enables amph-vax boosting to be applied to any clinically relevant CAR-T cell product.<\/jats:p>","DOI":"10.1038\/s41551-025-01470-0","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T09:05:05Z","timestamp":1756112705000},"page":"711-731","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1809-248X","authenticated-orcid":false,"given":"Tomasz M.","family":"Grzywa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Neeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjani","family":"Ramasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1239-4946","authenticated-orcid":false,"given":"Anna","family":"Romanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3979-7567","authenticated-orcid":false,"given":"Ryan","family":"Tannir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen K.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Cossette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3253-1362","authenticated-orcid":false,"given":"Duncan M.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Sukaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9960-3674","authenticated-orcid":false,"given":"Elisa","family":"Bergaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2996-8034","authenticated-orcid":false,"given":"Stephan","family":"Kadauke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina M.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-0194","authenticated-orcid":false,"given":"Luca","family":"Paruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Ghilardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Cozzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Yousefpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuhbet","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikyung","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5811","authenticated-orcid":false,"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8030-7595","authenticated-orcid":false,"given":"Stephan A.","family":"Grupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1564-8531","authenticated-orcid":false,"given":"Roberto","family":"Chiarle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2398-5896","authenticated-orcid":false,"given":"K. Dane","family":"Wittrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0583-7470","authenticated-orcid":false,"given":"Leyuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8637-1405","authenticated-orcid":false,"given":"Darrell J.","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"1470_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1470_CR2","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1126\/science.abq6990","volume":"378","author":"DJ Irvine","year":"2022","unstructured":"Irvine, D. J., Maus, M. V., Mooney, D. J. & Wong, W. W. The future of engineered immune cell therapies. Science 378, 853\u2013858 (2022).","journal-title":"Science"},{"key":"1470_CR3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635\u2013648 (2023).","journal-title":"Nature"},{"key":"1470_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj2820","volume":"8","author":"Z Bai","year":"2022","unstructured":"Bai, Z. et al. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Sci. Adv. 8, eabj2820 (2022).","journal-title":"Sci. Adv."},{"key":"1470_CR5","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang, X. & Rivi\u00e8re, I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol. Ther. Oncolytics 3, 16015 (2016).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1470_CR6","doi-asserted-by":"publisher","first-page":"100385","DOI":"10.1016\/j.iotech.2023.100385","volume":"19","author":"A Neeser","year":"2023","unstructured":"Neeser, A., Ramasubramanian, R., Wang, C. & Ma, L. Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors. Immuno-Oncol. Technol. 19, 100385 (2023).","journal-title":"Immuno-Oncol. Technol."},{"key":"1470_CR7","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","volume":"3","author":"AL Garfall","year":"2019","unstructured":"Garfall, A. L. et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 3, 2812\u20132815 (2019).","journal-title":"Blood Adv."},{"key":"1470_CR8","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. CD19 CAR\u2013T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123\u20132138 (2016).","journal-title":"J. Clin. Invest."},{"key":"1470_CR9","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1200\/JCO.20.02477","volume":"39","author":"S Kadauke","year":"2021","unstructured":"Kadauke, S. et al. Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial. J. Clin. Oncol. 39, 920\u2013930 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1470_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nri2274","volume":"8","author":"RA Seder","year":"2008","unstructured":"Seder, R. A., Darrah, P. A. & Roederer, M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8, 247\u2013258 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"1470_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543, 113\u2013117 (2017).","journal-title":"Nature"},{"key":"1470_CR12","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/leu.2017.39","volume":"31","author":"C Rossig","year":"2017","unstructured":"Rossig, C. et al. Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia. Leukemia 31, 1087\u20131095 (2017).","journal-title":"Leukemia"},{"key":"1470_CR13","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/blood-2017-08-802926","volume":"132","author":"Y Akahori","year":"2018","unstructured":"Akahori, Y. et al. Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination. Blood 132, 1134\u20131145 (2018).","journal-title":"Blood"},{"key":"1470_CR14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1126\/science.aav8692","volume":"365","author":"L Ma","year":"2019","unstructured":"Ma, L. et al. Enhanced CAR\u2013T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science 365, 162\u2013168 (2019).","journal-title":"Science"},{"key":"1470_CR15","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma, L. et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell 186, 3148\u20133165.e20 (2023).","journal-title":"Cell"},{"key":"1470_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nbt0697-553","volume":"15","author":"ET Boder","year":"1997","unstructured":"Boder, E. T. & Wittrup, K. D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15, 553\u2013557 (1997).","journal-title":"Nat. Biotechnol."},{"key":"1470_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147\u2013167 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1470_CR18","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1470_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.19.01892","volume":"38","author":"NV Frey","year":"2019","unstructured":"Frey, N. V. et al. Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia. J. Clin. Oncol. 38, 415\u2013422 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1470_CR20","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545\u20132554 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1470_CR21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1470_CR22","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41375-023-02129-y","volume":"38","author":"L Fischer","year":"2024","unstructured":"Fischer, L. et al. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed\/refractory myeloma. Leukemia 38, 372\u2013382 (2024).","journal-title":"Leukemia"},{"key":"1470_CR23","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1084\/jem.179.5.1539","volume":"179","author":"WY Ho","year":"1994","unstructured":"Ho, W. Y., Cooke, M. P., Goodnow, C. C. & Davis, M. M. Resting and anergic B cells are defective in CD28-dependent costimulation of naive CD4+ T cells. J. Exp. Med. 179, 1539\u20131549 (1994).","journal-title":"J. Exp. Med."},{"key":"1470_CR24","doi-asserted-by":"publisher","first-page":"e45185","DOI":"10.1371\/journal.pone.0045185","volume":"7","author":"TS Lim","year":"2012","unstructured":"Lim, T. S. et al. CD80 and CD86 differentially regulate mechanical interactions of T-cells with antigen-presenting dendritic cells and B-cells. PLoS ONE 7, e45185 (2012).","journal-title":"PLoS ONE"},{"key":"1470_CR25","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.ccell.2020.04.015","volume":"37","author":"MT Witkowski","year":"2020","unstructured":"Witkowski, M. T. et al. Extensive remodeling of the immune microenvironment in B cell acute lymphoblastic leukemia. Cancer Cell 37, 867\u2013882.e12 (2020).","journal-title":"Cancer Cell"},{"key":"1470_CR26","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1021\/acs.biochem.9b00808","volume":"58","author":"JR Klesmith","year":"2019","unstructured":"Klesmith, J. R., Wu, L., Lobb, R. R., Rennert, P. D. & Hackel, B. J. Fine epitope mapping of the CD19 extracellular domain promotes design. Biochemistry 58, 4869\u20134881 (2019).","journal-title":"Biochemistry"},{"key":"1470_CR27","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1021\/acssynbio.1c00010","volume":"10","author":"E Laurent","year":"2021","unstructured":"Laurent, E. et al. Directed evolution of stabilized monomeric CD19 for monovalent CAR interaction studies and monitoring of CAR-T cell patients. ACS Synth. Biol. 10, 1184\u20131198 (2021).","journal-title":"ACS Synth. Biol."},{"key":"1470_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adf1426","volume":"8","author":"C He","year":"2023","unstructured":"He, C. et al. CD19 CAR antigen engagement mechanisms and affinity tuning. Sci. Immunol. 8, eadf1426 (2023).","journal-title":"Sci. Immunol."},{"key":"1470_CR29","doi-asserted-by":"publisher","first-page":"100297","DOI":"10.1016\/j.xcrm.2021.100297","volume":"2","author":"N Li","year":"2021","unstructured":"Li, N. et al. CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice. Cell Rep. Med. 2, 100297 (2021).","journal-title":"Cell Rep. Med."},{"key":"1470_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi1145","volume":"15","author":"N Wellhausen","year":"2023","unstructured":"Wellhausen, N. et al. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. Sci. Transl. Med. 15, eadi1145 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1470_CR31","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.15252\/embr.201642943","volume":"17","author":"S Melnikov","year":"2016","unstructured":"Melnikov, S. et al. Molecular insights into protein synthesis with proline residues. EMBO Rep. 17, 1776\u20131784 (2016).","journal-title":"EMBO Rep."},{"key":"1470_CR32","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","volume":"25","author":"AJ Walker","year":"2017","unstructured":"Walker, A. J. et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. Mol. Ther. 25, 2189\u20132201 (2017).","journal-title":"Mol. Ther."},{"key":"1470_CR33","doi-asserted-by":"publisher","first-page":"eaau9732","DOI":"10.1126\/scitranslmed.aau9732","volume":"11","author":"R Sano","year":"2019","unstructured":"Sano, R. et al. An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma. Sci. Transl. Med. 11, eaau9732 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1470_CR34","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41698-023-00449-x","volume":"7","author":"A Shreenivas","year":"2023","unstructured":"Shreenivas, A. et al. ALK fusions in the pan-cancer setting: another tumor-agnostic target? npj Precis. Oncol. 7, 101 (2023).","journal-title":"npj Precis. Oncol."},{"key":"1470_CR35","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/j.ccell.2023.11.004","volume":"41","author":"E Bergaggio","year":"2023","unstructured":"Bergaggio, E. et al. ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. Cancer Cell 41, 2100\u20132116.e10 (2023).","journal-title":"Cancer Cell"},{"key":"1470_CR36","doi-asserted-by":"publisher","first-page":"10679","DOI":"10.1073\/pnas.97.20.10679","volume":"97","author":"J Foote","year":"2000","unstructured":"Foote, J. & Eisen, H. N. Breaking the affinity ceiling for antibodies and T cell receptors. Proc. Natl Acad. Sci. USA 97, 10679\u201310681 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1470_CR37","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"1470_CR38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S0076-6879(04)83004-0","volume":"383","author":"CA Rohl","year":"2004","unstructured":"Rohl, C. A., Strauss, C. E. M., Misura, K. M. S. & Baker, D. Protein structure prediction using Rosetta. Methods Enzymol. 383, 66\u201393 (2004).","journal-title":"Methods Enzymol."},{"key":"1470_CR39","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jmb.2007.05.022","volume":"372","author":"E Krissinel","year":"2007","unstructured":"Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774\u2013797 (2007).","journal-title":"J. Mol. Biol."},{"key":"1470_CR40","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nature10429","volume":"478","author":"DL Burdette","year":"2011","unstructured":"Burdette, D. L. et al. STING is a direct innate immune sensor of cyclic-di-GMP. Nature 478, 515\u2013518 (2011).","journal-title":"Nature"},{"key":"1470_CR41","doi-asserted-by":"publisher","first-page":"e004483","DOI":"10.1136\/jitc-2021-004483","volume":"10","author":"EM Holland","year":"2022","unstructured":"Holland, E. M. et al. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. J. Immunother. Cancer 10, e004483 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1470_CR42","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/318533a0","volume":"318","author":"JM Adams","year":"1985","unstructured":"Adams, J. M. et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533\u2013538 (1985).","journal-title":"Nature"},{"key":"1470_CR43","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jmb.2004.08.019","volume":"343","author":"KS Midelfort","year":"2004","unstructured":"Midelfort, K. S. et al. Substantial energetic improvement with minimal structural perturbation in a high affinity mutant antibody. J. Mol. Biol. 343, 685\u2013701 (2004).","journal-title":"J. Mol. Biol."},{"key":"1470_CR44","doi-asserted-by":"publisher","first-page":"101161","DOI":"10.1016\/j.xcrm.2023.101161","volume":"4","author":"M Boulch","year":"2023","unstructured":"Boulch, M. et al. A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy. Cell Rep. Med. 4, 101161 (2023).","journal-title":"Cell Rep. Med."},{"key":"1470_CR45","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T. et al. CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731\u2013738 (2018).","journal-title":"Nat. Med."},{"key":"1470_CR46","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nri3311","volume":"12","author":"LD Shultz","year":"2012","unstructured":"Shultz, L. D., Brehm, M. A., Garcia-Martinez, J. V. & Greiner, D. L. Humanized mice for immune system investigation: progress, promise and challenges. Nat. Rev. Immunol. 12, 786\u2013798 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"1470_CR47","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1084\/jem.194.5.657","volume":"194","author":"JP Medema","year":"2001","unstructured":"Medema, J. P. et al. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte\u2013induced apoptosis. J. Exp. Med. 194, 657\u2013668 (2001).","journal-title":"J. Exp. Med."},{"key":"1470_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18570-x","volume":"11","author":"Q Peng","year":"2020","unstructured":"Peng, Q. et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat. Commun. 11, 4835 (2020).","journal-title":"Nat. Commun."},{"key":"1470_CR49","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/s41551-022-00896-0","volume":"6","author":"KS Gordon","year":"2022","unstructured":"Gordon, K. S. et al. Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains. Nat. Biomed. Eng. 6, 855\u2013866 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"1470_CR50","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 602, 503\u2013509 (2022).","journal-title":"Nature"},{"key":"1470_CR51","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1126\/science.aay5967","volume":"367","author":"K Reinhard","year":"2020","unstructured":"Reinhard, K. et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science 367, 446\u2013453 (2020).","journal-title":"Science"},{"key":"1470_CR52","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581\u2013590 (2015).","journal-title":"Nat. Med."},{"key":"1470_CR53","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","volume":"17","author":"A Ajina","year":"2018","unstructured":"Ajina, A. & Maher, J. Strategies to address chimeric antigen receptor tonic signaling. Mol. Cancer Ther. 17, 1795\u20131815 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"1470_CR54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","volume":"21","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva, D. et al. Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent. Cell Rep. 21, 17\u201326 (2017).","journal-title":"Cell Rep."},{"key":"1470_CR55","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood.2020006770","volume":"137","author":"J Gauthier","year":"2021","unstructured":"Gauthier, J. et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood 137, 323\u2013335 (2021).","journal-title":"Blood"},{"key":"1470_CR56","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1182\/blood-2021-147299","volume":"138","author":"RM Myers","year":"2021","unstructured":"Myers, R. M. et al. Outcomes after reinfusion of CD19-specific chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed\/refractory B-cell acute lymphoblastic leukemia. Blood 138, 474 (2021).","journal-title":"Blood"},{"key":"1470_CR57","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","volume":"18","author":"DL Wagner","year":"2021","unstructured":"Wagner, D. L. et al. Immunogenicity of CAR T cells in cancer therapy. Nat. Rev. Clin. Oncol. 18, 379\u2013393 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1470_CR58","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1182\/bloodadvances.2020004038","volume":"5","author":"S Faude","year":"2021","unstructured":"Faude, S. et al. Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse. Blood Adv. 5, 2128\u20132136 (2021).","journal-title":"Blood Adv."},{"key":"1470_CR59","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1084\/jem.20182375","volume":"216","author":"M Cazaux","year":"2019","unstructured":"Cazaux, M. et al. Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity. J. Exp. Med. 216, 1038\u20131049 (2019).","journal-title":"J. Exp. Med."},{"key":"1470_CR60","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.3390\/vaccines10111845","volume":"10","author":"S Michaelides","year":"2022","unstructured":"Michaelides, S., Obeck, H., Kechur, D., Endres, S. & Kobold, S. Migratory engineering of T cells for cancer therapy. Vaccines 10, 1845 (2022).","journal-title":"Vaccines"},{"key":"1470_CR61","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda, S. M. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 21, 47\u201366 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1470_CR62","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat. Med. 29, 2844\u20132853 (2023).","journal-title":"Nat. Med."},{"key":"1470_CR63","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-1-62703-992-5_10","volume":"1131","author":"JAV Deventer","year":"2014","unstructured":"Deventer, J. A. V. & Wittrup, K. D. Monoclonal antibodies, methods and protocols. Methods Mol. Biol. 1131, 151\u2013181 (2014).","journal-title":"Methods Mol. Biol."},{"key":"1470_CR64","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-2748-7_1","volume":"1319","author":"A Angelini","year":"2015","unstructured":"Angelini, A. et al. Protein engineering and selection using yeast surface display. Methods Mol. Biol. 1319, 3\u201336 (2015).","journal-title":"Methods Mol. Biol."},{"key":"1470_CR65","doi-asserted-by":"publisher","first-page":"252ra121","DOI":"10.1126\/scitranslmed.3009073","volume":"6","author":"L Ma","year":"2014","unstructured":"Ma, L. et al. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci. Transl. Med. 6, 252ra121 (2014).","journal-title":"Sci. Transl. Med."},{"key":"1470_CR66","doi-asserted-by":"publisher","first-page":"7007","DOI":"10.1039\/C6SC02285E","volume":"7","author":"CMBK Kourra","year":"2016","unstructured":"Kourra, C. M. B. K. & Cramer, N. Converting disulfide bridges in native peptides to stable methylene thioacetals. Chem. Sci. 7, 7007\u20137012 (2016).","journal-title":"Chem. Sci."},{"key":"1470_CR67","doi-asserted-by":"publisher","first-page":"6201","DOI":"10.1021\/acs.jctc.6b00819","volume":"12","author":"H Park","year":"2016","unstructured":"Park, H. et al. Simultaneous optimization of biomolecular energy functions on features from small molecules and macromolecules. J. Chem. Theory Comput. 12, 6201\u20136212 (2016).","journal-title":"J. Chem. Theory Comput."},{"key":"1470_CR68","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1021\/acs.jctc.7b00125","volume":"13","author":"RF Alford","year":"2017","unstructured":"Alford, R. F. et al. The Rosetta all-atom energy function for macromolecular modeling and design. J. Chem. Theory Comput. 13, 3031\u20133048 (2017).","journal-title":"J. Chem. Theory Comput."},{"key":"1470_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059004","volume":"8","author":"LG Niv\u00f3n","year":"2013","unstructured":"Niv\u00f3n, L. G., Moretti, R. & Baker, D. A Pareto-optimal refinement method for protein design scaffolds. PLoS ONE 8, e59004 (2013).","journal-title":"PLoS ONE"},{"key":"1470_CR70","doi-asserted-by":"publisher","first-page":"7.32.1","DOI":"10.1002\/0471142735.im0732s99","volume":"99","author":"S Nair","year":"2012","unstructured":"Nair, S., Archer, G. E. & Tedder, T. F. Isolation and generation of human dendritic cells. Curr. Protoc. Immunol. 99, 7.32.1\u20137.32.23 (2012).","journal-title":"Curr. Protoc. Immunol."},{"key":"1470_CR71","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/CJI.0b013e31819e1773","volume":"32","author":"TH Han","year":"2009","unstructured":"Han, T. H. et al. Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferon-gamma. J. Immunother. 32, 399\u2013407 (2009).","journal-title":"J. Immunother."},{"key":"1470_CR72","doi-asserted-by":"publisher","first-page":"e61338","DOI":"10.1371\/journal.pone.0061338","volume":"8","author":"ML Davila","year":"2013","unstructured":"Davila, M. L., Kloss, C. C., Gunset, G. & Sadelain, M. CD19 CAR-targeted T cells induce long-term remission and B cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS ONE 8, e61338 (2013).","journal-title":"PLoS ONE"},{"key":"1470_CR73","doi-asserted-by":"publisher","first-page":"303","DOI":"10.4103\/0976-500X.119726","volume":"4","author":"J Charan","year":"2013","unstructured":"Charan, J. & Kantharia, N. D. How to calculate sample size in animal studies? J. Pharm. Pharmacother. 4, 303\u2013306 (2013).","journal-title":"J. Pharm. Pharmacother."},{"key":"1470_CR74","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/nm.4200","volume":"22","author":"KD Moynihan","year":"2016","unstructured":"Moynihan, K. D. et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat. Med. 22, 1402\u20131410 (2016).","journal-title":"Nat. Med."},{"key":"1470_CR75","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi, K. et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat. Biotechnol. 36, 346\u2013351 (2018).","journal-title":"Nat. Biotechnol."}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01470-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01470-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01470-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T22:02:31Z","timestamp":1776808951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01470-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":75,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1470"],"URL":"https:\/\/doi.org\/10.1038\/s41551-025-01470-0","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"17 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.M. and D.J.I. are inventors on patents filed related to the amphiphile-mimotope vaccine technology (WO2021221782A1, WO2021221783A1), which has been licensed to Elicio Therapeutics. D.J.I. is a consultant and holds equity in Elicio Therapeutics. G.G. served as a scientific consultant for viTToria Biotherapeutics. M.R. holds patents related to CD19 CAR-T cells, served as a consultant for NanoString, Bristol Myers Squibb, GlaxoSmithKline, Scaylite, Bayer and AbClon, and receives research funding from AbClon, NanoString, Oxford NanoImaging, viTToria Biotherapeutics, CURIOX and Beckman Coulter. M.R. is the scientific founder of viTToria Biotherapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}